TY - JOUR
T1 - Controlled release of transforming growth factor β1 from biodegradable polymer microparticles
AU - Lu, Lichun
AU - Stamatas, Georgios N.
AU - Mikos, Antonios G.
PY - 2000
Y1 - 2000
N2 - Recombinant human transforming growth factor β1 (TGF-β1) was incorporated into biodegradable microparticles of blends of poly(DL-lactic- co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) at 6 ng/1 mg microparticles. Fluorescein isothiocynate labeled bovine serum albumin (FITC- BSA) was coencapsulated as a porogen at 4 μg/1 mg of microparticles. The effects of PEG content (0, 1, or 5 wt %) and buffer pH (3, 5, or 7.4) on the protein release kinetics and the degradation of PLGA were determined in vitro for up to 28 days. The entrapment yield of TGF-β1 was 83.4 ± 13.1 and 54.2 ± 12.1% for PEG contents of 0 and 5%, respectively. The F1TC-BSA and TGF-β1 were both released in a multiphasic fashion including an initial burst effect. Increasing the PEG content resulted in the decreased cumulative mass of released proteins. By day 28, 3.8 ± 0.1 and 2.8 ± 0.3 μg (based on 1 mg microparticles) of loaded FITC-BSA and 3.4 ±- 0.2 and 2.2 ± 0.3 ng of loaded TGF-β1 were released into pH 7.4 phosphate buffered saline (PBS) from microparticles with 0 and 5% PEG, respectively. Aggregation of FITC-BSA occurred at lower buffer pH, which led to decreased release rates of both proteins. For microparticles with 5% PEG, 2.3 ± 0.1 μg of FiTC-BSA and 2.0 ± 0.2 ng of TGF-β1 were released in pH 7.4 buffer after 28 days, while only 1.7 ± 0.3 μg and 1.3 ± 0.4 ng of the corresponding proteins were released in pH 3 buffer. The degradation of PLGA was also enhanced at 5% PEG content, which was significantly accelerated at acidic pH conditions. The calculated half-lives of PLGA were 20.3 ± 0.9 and 15.9 ± 1.2 days for PEG contents of 0 and 5%, respectively, in pH 7.4 PBS and 14.8 ± 0.4 and 5.5 ± 0.1 days for 5% PEG in pH 7.4 and 3 buffers, respectively. These results suggest that PLGA/PEG blend microparticles are useful as delivery vehicles for controlled release of growth factors. (C) 2000 John Wiley and Sons, Inc.
AB - Recombinant human transforming growth factor β1 (TGF-β1) was incorporated into biodegradable microparticles of blends of poly(DL-lactic- co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) at 6 ng/1 mg microparticles. Fluorescein isothiocynate labeled bovine serum albumin (FITC- BSA) was coencapsulated as a porogen at 4 μg/1 mg of microparticles. The effects of PEG content (0, 1, or 5 wt %) and buffer pH (3, 5, or 7.4) on the protein release kinetics and the degradation of PLGA were determined in vitro for up to 28 days. The entrapment yield of TGF-β1 was 83.4 ± 13.1 and 54.2 ± 12.1% for PEG contents of 0 and 5%, respectively. The F1TC-BSA and TGF-β1 were both released in a multiphasic fashion including an initial burst effect. Increasing the PEG content resulted in the decreased cumulative mass of released proteins. By day 28, 3.8 ± 0.1 and 2.8 ± 0.3 μg (based on 1 mg microparticles) of loaded FITC-BSA and 3.4 ±- 0.2 and 2.2 ± 0.3 ng of loaded TGF-β1 were released into pH 7.4 phosphate buffered saline (PBS) from microparticles with 0 and 5% PEG, respectively. Aggregation of FITC-BSA occurred at lower buffer pH, which led to decreased release rates of both proteins. For microparticles with 5% PEG, 2.3 ± 0.1 μg of FiTC-BSA and 2.0 ± 0.2 ng of TGF-β1 were released in pH 7.4 buffer after 28 days, while only 1.7 ± 0.3 μg and 1.3 ± 0.4 ng of the corresponding proteins were released in pH 3 buffer. The degradation of PLGA was also enhanced at 5% PEG content, which was significantly accelerated at acidic pH conditions. The calculated half-lives of PLGA were 20.3 ± 0.9 and 15.9 ± 1.2 days for PEG contents of 0 and 5%, respectively, in pH 7.4 PBS and 14.8 ± 0.4 and 5.5 ± 0.1 days for 5% PEG in pH 7.4 and 3 buffers, respectively. These results suggest that PLGA/PEG blend microparticles are useful as delivery vehicles for controlled release of growth factors. (C) 2000 John Wiley and Sons, Inc.
KW - Biodegradable microparticles
KW - Bone regeneration
KW - Growth factor delivery
KW - Poly(DL-lactic-co-glycolic acid)
KW - Poly(ethylene glycol)
KW - Polymer blends
KW - Transforming growth factor β1
UR - http://www.scopus.com/inward/record.url?scp=0034069615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034069615&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-4636(20000605)50:3<440::AID-JBM19>3.0.CO;2-G
DO - 10.1002/(SICI)1097-4636(20000605)50:3<440::AID-JBM19>3.0.CO;2-G
M3 - Article
C2 - 10737887
AN - SCOPUS:0034069615
SN - 0021-9304
VL - 50
SP - 440
EP - 451
JO - Journal of Biomedical Materials Research
JF - Journal of Biomedical Materials Research
IS - 3
ER -